Endospan received U.S. premarket approval for its Nexus aortic arch stent graft, bringing the company closer to its planned acquisition by Artivion. The agreement gives Artivion an option to acquire Endospan at any time within 90 days of FDA approval. Nexus is described as a bimodular aortic arch stent graft designed to mimic ascending and arch anatomy, aiming to enable minimally invasive treatment for aortic arch disease. The device approval removes one key regulatory step ahead of deal closure. The report underscores how device approvals can accelerate timelines for transactions in cardiovascular med-tech, where distribution and market authorization holders drive value.